Skip to main navigation Skip to search Skip to main content

Lipocalin-2 is increased in amyotrophic lateral sclerosis

  • Tiziana Petrozziello
  • , Alexandra N. Mills
  • , Sali M.K. Farhan
  • , Kaly A. Mueller
  • , Eric J. Granucci
  • , Kelly E. Glajch
  • , James Chan
  • , Sheena Chew
  • , James D. Berry
  • , Ghazaleh Sadri-Vakili

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Background: The exact mechanisms underlying neuroinflammation and how they contribute to amyotrophic lateral sclerosis (ALS) pathogenesis remain unclear. One possibility is the secretion of neurotoxic factors, such as lipocalin-2 (LCN2), that lead to neuronal death. Methods: LCN2 levels were measured in human postmortem tissue using Western blot, quantitative real time polymerase chain reaction, and immunofluorescence, and in plasma by enzyme-linked immunosorbent assay. SH-SY5Y cells were used to test the pro-inflammatory effects of LCN2. Results: LCN2 is increased in ALS postmortem motor cortex, spinal cord, and plasma. Furthermore, we identified several LCN2 variants in ALS patients that may contribute to disease pathogenesis. Lastly, while LCN2 treatment caused cell death and increased pro-inflammatory markers, treatment with an anti-LCN2 antibody prevented these responses in vitro. Conclusions: LCN2 upregulation in ALS postmortem samples and plasma may be an upstream event for triggering neuroinflammation and neuronal death.

Original languageEnglish
Pages (from-to)272-283
Number of pages12
JournalMuscle and Nerve
Volume62
Issue number2
DOIs
StatePublished - 1 Aug 2020
Externally publishedYes

Keywords

  • amyotrophic lateral sclerosis
  • biomarker
  • cell death
  • lipocalin-2
  • neuroinflammation

Fingerprint

Dive into the research topics of 'Lipocalin-2 is increased in amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this